Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Hansa Biopharma AB. The associated price target remains the same with SEK143.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight the potential of Hansa Biopharma AB’s imlifidase as a standard pre-treatment for AAV-based gene therapies. Recent successes, such as the treatment of seropositive patients with gene therapy following imlifidase pretreatment, underscore its efficacy and safety, which are crucial for patients with rare genetic diseases who often have pre-existing neutralizing antibodies. This development is particularly significant given the challenges these antibodies pose to effective treatment.
Furthermore, the expansion of AAV-based gene therapy is seen as a positive catalyst for Hansa’s growth prospects. The valuation of Hansa is based on a risk-adjusted revenue estimate, considering the probability of success of its pipeline assets. Despite some risks, such as financial needs and regulatory hurdles, the promising outlook for imlifidase in various indications supports the Buy rating with a price target of SEK143.
According to TipRanks, Tsao is a 5-star analyst with an average return of 15.9% and a 52.23% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Hansa Biopharma AB, Protagonist Therapeutics, and Praxis Precision Medicines.